Attached files
| file | filename |
|---|---|
| S-1/A - CorMedix Inc. | v173445_s1a.htm |
| EX-3.3 - CorMedix Inc. | v173445_ex3-3.htm |
| EX-3.4 - CorMedix Inc. | v173445_ex3-4.htm |
| EX-23.1 - CorMedix Inc. | v173445_ex23-1.htm |
| EX-10.8 - CorMedix Inc. | v173445_ex10-8.htm |
| EX-10.9 - CorMedix Inc. | v173445_ex10-9.htm |
| EX-10.7 - CorMedix Inc. | v173445_ex10-7.htm |
| EX-10.13 - CorMedix Inc. | v173445_ex10-13.htm |
| EX-10.16 - CorMedix Inc. | v173445_ex10-16.htm |
| EX-10.17 - CorMedix Inc. | v173445_ex10-17.htm |
Exhibit
10.15
AMENDMENT TO CONTRIBUTION
AGREEMENT
This
Amendment (this “Amendment”), executed as of February 22, 2010, to that certain
Contribution Agreement originally executed as of July 28, 2006 and amended as of
October 6, 2009 by the parties hereto (as so amended, the “Agreement”), is
entered into by and between SHIVA BIOMEDICAL, LLC, a
limited liability company duly organized under the laws of New Jersey having a
place of business at 10810 Executive Center Drive, Danville Building, Suite 100,
Little Rock, AR 22211 (“Shiva”), and CORMEDIX, INC., formerly PICTON HOLDING COMPANY, INC.
and successor in interest to PICTON PHARMACEUTICALS, INC.,
a corporation duly organized and existing under the laws of the State of
Delaware having a place of business at 86 Summit Avenue, Suite 301, Summit,
NJ 07901 (the “Company”).
WHEREAS, the parties hereto
desire to amend certain provisions of the Agreement as set forth
herein;
NOW, THEREFORE, in
consideration of the premises and the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto, intending to be legally bound, agree as
follows:
|
|
1.
|
Capitalized
terms used herein and not otherwise defined shall have the meanings given
to them in the Agreement. All references to an Article shall
refer to an Article of the Agreement unless otherwise
indicated.
|
|
|
2.
|
Paragraph
(d) of Article 10.4.2 is hereby amended and restated in its
entirety as follows:
|
|
|
(d)
|
the
Company has not initiated patient dosing in a “Proof of Concept Trial” for
a Licensed Product on or before June 30, 2010, where a “Proof of Concept
Trial” is a Phase II clinical study as and to the extent defined for the
United States in 21 C.F.R. § 312.21(b), or its successor regulation, or
the equivalent regulation in any other country;
or
|
|
|
3.
|
This
Amendment shall be in full force and effect from and after the date
hereof. Except as amended hereby, the Agreement shall remain in
full force and effect.
|
|
|
4.
|
This
Amendment may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and
the same instrument. This Amendment may be signed and delivered to the
other parties by facsimile signature; such transmission will be deemed a
valid signature.
|
[SIGNATURE PAGE
FOLLOWS]
IN WITNESS WHEREOF, the
parties hereto have executed this Amendment, in triplicate by proper persons
thereunto duly authorized.
|
CORMEDIX,
INC.
|
SHIVA
BIOMEDICAL, LLC
|
| By: |
/s/
John C. Houghton
|
By: |
/s/
Yashvant Patel
|
| Name: |
John
C. Houghton
|
Name: |
Yashvant
Patel
|
| Title: |
President
and CEO
|
Title: |
Vice
President
|
| Date: |
2/22/2010
|
Date: |
2/22/2010
|